CCL2 and metabolic dysfunction-associated steatohepatitis: Furthermore, it decreases the hepatic expression of inflammatory cytokines (e.g., TNF-α, interleukin-6, and Monocyte Chemoattractant Protein-1 (MCP-1)) in NASH patients.